Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)
- Authors
- Lau, G[Lau, George]; Cheng, AL[Cheng, Ann-Lii]; Sangro, B[Sangro, Bruno]; Kudo, M[Kudo, Masatoshi]; Kelley, RK[Kelley, Robin Kate]; Tak, WY[Tak, Won Young]; Gasbarrini, A[Gasbarrini, Antonio]; Reig, M[Reig, Maria]; Lim, HY[Lim, Ho Yeong]; Tougeron, D[Tougeron, David]; De Toni, EN[De Toni, Enrico N.]; Tam, VC[Tam, Vincent C.]; Mody, K[Mody, Kabir]; Gong, J[Gong, Jun]; Mccoy, CL[Mccoy, Carrie L.]; Gupta, C[Gupta, Charu]; Makowsky, M[Makowsky, Mallory]; Negro, A[Negro, Alejandra]; Abou-Alfa, GK[Abou-Alfa, Ghassan K.]
- Issue Date
- 1-Jun-2023
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.41, no.16
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 41
- Number
- 16
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.